The DLBCL90 gene‐expression assay identifies double‐hit lymphomas with high sensitivity in patients from two phase II clinical trials with high‐risk diffuse large B‐cell lymphoma

• Kathrine T. Isaksen,
• Klaus Beiske,
• Erlend B. Smeland,
• Judit Jørgensen,
• Marianne Brodtkorb,
• June Helen Myklebust,
• Mats Jerkeman,
• Leo Meriranta,
• Marja‐Liisa Karjalainen‐Lindsberg,
• Sirpa Leppä,
• David W. Scott,
• Harald Holte,
• Yngvild Nuvin Blaker

Affiliations

Kathrine T. Isaksen

Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway

Klaus Beiske

Institute of Clinical Medicine University of Oslo Oslo Norway

Erlend B. Smeland

Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway

Judit Jørgensen

Department of Hematology Aarhus University Hospital Aarhus Denmark

Marianne Brodtkorb

Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway

June Helen Myklebust

Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway

Mats Jerkeman

Department of Oncology Lund University and Skåne University Hospital Lund Sweden

Leo Meriranta

Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki Helsinki Finland

Marja‐Liisa Karjalainen‐Lindsberg

Department of Pathology Helsinki University Hospital Helsinki Finland

Sirpa Leppä

Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki Helsinki Finland

David W. Scott

Centre for Lymphoid Cancer British Columbia Cancer Vancouver Canada

Harald Holte

KG Jebsen Centre for B cell malignancies University of Oslo Oslo Norway

Yngvild Nuvin Blaker

Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway